PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).
Mohammad Atiq(Memorial Sloan Kettering Cancer Center), Ravi A. Madan(National Cancer Institute), William L. Dahut(National Cancer Institute), Munjid Al Harthy(Sultan Qaboos University), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), James L. Gulley(National Cancer Institute), David James VanderWeele(Northwestern University), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Elias Bin Aris Chandran(National Institutes of Health), Anna Couvillon(National Institutes of Health), Gang Chen(Fudan University), Monique Williams(National Institutes of Health), Helen Owens(National Institutes of Health), Shruti U. Gandhy(Texas A&M Health Science Center)
Cited by 1
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817